Drug-coated balloons (DCB)

News

News: BD Announces Clinical Trial Data for the Lutonix 014 Drug-Coated Balloon Below-The-Knee IDE Trial

11/27/2018

Safety and efficacy results presented during late-breaking clinical trials session at VIVA 2018.

Safety and efficacy results...

11/27/2018

Cath Lab Digest

New, Longer 220 mm Length of Lutonix 035 Drug-Coated Balloon Reduces Cost at Arkansas Heart Hospital

11/27/2018

Ian M. Cawich , MD;

The newest device that we have been able to use has been the 220 mm length version of the Lutonix 035 drug-coated balloon (BD/Bard). We have used this product since it launched in August and have done six cases thus far, all with great...

The newest device that we have...

11/27/2018

Cath Lab Digest

Clinical News

News: C.R. Bard Receives FDA Premarket Approval of the Lutonix 035 Drug-Coated Balloon as the First and Only DCB for the Treatment of Patients with Dysfunctional AV Fistulae

10/01/2017

New Option to Preserve Vascular Access and Help Hemodialysis Patients Extend Time Between Reinterventions

New Option to Preserve Vascular...

10/01/2017

Cath Lab Digest

A Real-World Comparison of IN.PACT vs Lutonix Drug-Coated Balloons in Complex Lesions

03/03/2016

Sabine Steiner , MD, MSc;

Our study included 281 patients undergoing treatment with the IN.PACT drug-coated in 366 limbs. We also have about 137 patients treated with the Lutonix drug-coated balloon in 168 limbs.

Our study included 281 patients...

03/03/2016

Cath Lab Digest

Technology Pulse

The Drug-Coated Balloon: Not Just a Balloon

11/05/2014

Fadi Saab , MD, FACC, FSCAI;

Larry J. Diaz-Sandoval , MD;

Jihad A. Mustapha , MD, FACC, FSCAI;

The DCB represents a technology that is able to carry and deliver an anti-proliferative drug to the arterial wall at the same time the mechanical treatment is provided to the obstructive atherosclerotic plaque. Understanding this apparently...

The DCB represents a technology...

11/05/2014

Cath Lab Digest